Lake Street analyst Brooks O’Neil maintained a Buy rating on Tandem Diabetes Care (TNDM – Research Report) today and set a price target of $60.00. The company’s shares closed last Friday at $24.42.
O’Neil covers the Healthcare sector, focusing on stocks such as Harrow Health, Avita Medical, and Tandem Diabetes Care. According to TipRanks, O’Neil has an average return of 3.1% and a 49.75% success rate on recommended stocks.
In addition to Lake Street, Tandem Diabetes Care also received a Buy from Craig-Hallum’s Alexander Nowak in a report issued today. However, on February 13, Leerink Partners initiated coverage with a Hold rating on Tandem Diabetes Care (NASDAQ: TNDM).
See Insiders’ Hot Stocks on TipRanks >>
Based on Tandem Diabetes Care’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $185.62 million and a GAAP net loss of $32.96 million. In comparison, last year the company earned a revenue of $204.55 million and had a GAAP net loss of $48.97 million
Based on the recent corporate insider activity of 94 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TNDM in relation to earlier this year. Last month, Rajwant Sodhi, a Director at TNDM bought 1,070.00 shares for a total of $29,596.20.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tandem Diabetes Care (TNDM) Company Description:
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
Read More on TNDM:
